<DOC>
	<DOC>NCT02104037</DOC>
	<brief_summary>The purpose of this study is to investigate transfer of liraglutide from blood to cerebrospinal fluid.</brief_summary>
	<brief_title>Liraglutide in Spinal Fluid</brief_title>
	<detailed_description />
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes treated with liraglutide 1.8 mg for 1 month and 5% weight loss</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>